6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
assessed	VBD	assessed	assessed	assess	N	O
as	IN	as	a	as	N	O
causally	RB	causally	causally	causal	N	O
related	VBN	related	related	relat	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
investigator	NN	investigator	investigator	investig	N	O
or	CC	or	or	or	N	O
ADRs	NNP	adrs	adrs	adr	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Effects	NNS	effects	effect	effect	N	O
on	IN	on	on	on	N	O
serum	NN	serum	serum	serum	N	O
liver	NN	liver	liver	liver	N	O
biochemistries	NNS	biochemistries	biochemistry	biochemistri	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
or	CC	or	or	or	N	O
C	NNP	c	c	c	N	O
co	SYM	co	co	co	N	O
-	:	-	-	-	N	O
infection	NN	infection	infection	infect	Y	O
[	FW	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Fat	NNP	fat	fat	fat	N	B-AdverseReaction
Redistribution	NNP	redistribution	redistribution	redistribut	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Immune	NNP	immune	immune	immun	N	B-AdverseReaction
Reconstitution	NNP	reconstitution	reconstitution	reconstitut	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O

:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
moderate	JJ	moderate	moderate	moder	N	B-Severity
to	TO	to	to	to	N	O
severe	JJ	severe	severe	sever	N	B-Severity
intensity	NN	intensity	intensity	intens	N	O
and	CC	and	and	and	N	O
incidence	NN	incidence	incidence	incid	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
one	CD	one	one	one	N	O
adult	NN	adult	adult	adult	N	O
trial	NN	trial	trial	trial	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
insomnia	JJ	insomnia	insomnia	insomnia	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
ViiV	NNP	viiv	viiv	viiv	N	O
Healthcare	NNP	healthcare	healthcare	healthcar	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
877	CD	877	877	877	N	O
-	:	-	-	-	N	O
844	CD	844	844	844	N	O
-	:	-	-	-	N	O
8872	CD	8872	8872	8872	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	NN	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O
in	IN	in	in	in	N	O
Adult	NNP	adult	adult	adult	N	O
Subjects	NNS	subjects	subject	subject	N	O

Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	JJ	emergent	emergent	emerg	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Drug	NNP	drug	drug	drug	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
ADRs	NNP	adrs	adrs	adr	N	O
)	)	)	)	)	N	O

Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
naive	JJ	naive	naive	naiv	N	O
Subjects	NNS	subjects	subject	subject	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
assessment	NN	assessment	assessment	assess	N	O
of	IN	of	of	of	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
in	IN	in	in	in	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
infected	VBN	infected	infected	infect	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
naive	JJ	naive	naive	naiv	N	O
subjects	NNS	subjects	subject	subject	N	O
is	VBZ	is	is	is	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
analyses	NNS	analyses	analysis	analys	N	O
of	IN	of	of	of	N	O
96	CD	96	96	96	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
2	CD	2	2	2	N	O
international	JJ	international	international	intern	N	O
,	,	,	,	,	N	O
multicenter	NN	multicenter	multicenter	multicent	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
SPRING	NNP	spring	spring	spring	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
ING113086	NNP	ing113086	ing113086	ing113086	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
SINGLE	NNP	single	single	singl	N	O
(	(	(	(	(	N	O
ING114467	NNP	ing114467	ing114467	ing114467	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
48	CD	48	48	48	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
data	NNS	data	data	data	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
international	JJ	international	international	intern	N	O
,	,	,	,	,	N	O
multicenter	NN	multicenter	multicenter	multicent	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
FLAMINGO	NNP	flamingo	flamingo	flamingo	N	O
(	(	(	(	(	N	O
ING114915	NNP	ing114915	ing114915	ing114915	N	O
)	)	)	)	)	N	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
SPRING	NNP	spring	spring	spring	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
822	CD	822	822	822	N	O
subjects	NNS	subjects	subject	subject	N	O
were	VBD	were	were	were	N	O
randomized	VBN	randomized	randomized	random	N	O
and	CC	and	and	and	N	O
received	VBN	received	received	receiv	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
either	DT	either	either	either	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
or	CC	or	or	or	N	O
raltegravir	JJ	raltegravir	raltegravir	raltegravir	N	O
400	CD	400	400	400	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
both	DT	both	both	both	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
fixed	JJ	fixed	fixed	fix	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
dual	JJ	dual	dual	dual	N	O
nucleoside	JJ	nucleoside	nucleoside	nucleosid	N	O
reverse	NN	reverse	reverse	revers	N	O
transcriptase	NN	transcriptase	transcriptase	transcriptas	N	O
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	O
(	(	(	(	(	N	O
NRTI	NNP	nrti	nrti	nrti	N	O
)	)	)	)	)	N	O
treatment	NN	treatment	treatment	treatment	N	O
(	(	(	(	(	N	O
either	CC	either	either	either	N	O
abacavir	VB	abacavir	abacavir	abacavir	N	O
sulfate	NN	sulfate	sulfate	sulfat	N	O
and	CC	and	and	and	N	O
lamivudine	NN	lamivudine	lamivudine	lamivudin	N	O
[	NN	[	[	[	N	O
EPZICOM	NNP	epzicom	epzicom	epzicom	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
or	CC	or	or	or	N	O
emtricitabine	VB	emtricitabine	emtricitabine	emtricitabin	N	O
tenofovir	JJ	tenofovir	tenofovir	tenofovir	N	O
[	NNP	[	[	[	N	O
TRUVADA	NNP	truvada	truvada	truvada	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
])	NN	])	])	])	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
808	CD	808	808	808	N	O
subjects	NNS	subjects	subject	subject	N	O
included	VBN	included	included	includ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
and	CC	and	and	and	N	O
safety	NN	safety	safety	safeti	N	O
analyses	NNS	analyses	analysis	analys	N	O
.	.	.	.	.	N	O

Through	IN	through	through	through	N	O
96	CD	96	96	96	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
was	VBD	was	wa	wa	N	O
2%	CD	2%	2%	2%	N	O
in	IN	in	in	in	N	O
both	DT	both	both	both	N	O
treatment	NN	treatment	treatment	treatment	N	O
arms	NNS	arms	arm	arm	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
SINGLE	NNP	single	single	singl	N	O
,	,	,	,	,	N	O
833	CD	833	833	833	N	O
subjects	NNS	subjects	subject	subject	N	O
were	VBD	were	were	were	N	O
randomized	VBN	randomized	randomized	random	N	O
and	CC	and	and	and	N	O
received	VBN	received	received	receiv	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
either	DT	either	either	either	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
with	IN	with	with	with	N	O
fixed	JJ	fixed	fixed	fix	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
abacavir	JJ	abacavir	abacavir	abacavir	N	O
sulfate	NN	sulfate	sulfate	sulfat	N	O
and	CC	and	and	and	N	O
lamivudine	NN	lamivudine	lamivudine	lamivudin	N	O
(	(	(	(	(	N	O
EPZICOM	NNP	epzicom	epzicom	epzicom	N	O
)	)	)	)	)	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
or	CC	or	or	or	N	O
fixed	VBN	fixed	fixed	fix	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
efavirenz	JJ	efavirenz	efavirenz	efavirenz	N	O
emtricitabine	NN	emtricitabine	emtricitabine	emtricitabin	N	O
tenofovir	NN	tenofovir	tenofovir	tenofovir	N	O
(	(	(	(	(	N	O
ATRIPLA	NNP	atripla	atripla	atripla	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
)	)	)	)	)	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
.	.	.	.	.	N	O

Through	IN	through	through	through	N	O
96	CD	96	96	96	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
were	VBD	were	were	were	N	O
3%	CD	3%	3%	3%	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
EPZICOM	NNP	epzicom	epzicom	epzicom	N	O
and	CC	and	and	and	N	O
12%	CD	12%	12%	12%	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
ATRIPLA	NNP	atripla	atripla	atripla	N	O
once	RB	once	once	onc	N	O
daily	RB	daily	daily	daili	N	O
.	.	.	.	.	N	O

Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	NN	emergent	emergent	emerg	N	O
ADRs	NNP	adrs	adrs	adr	N	O
of	IN	of	of	of	N	O
moderate	JJ	moderate	moderate	moder	N	O
to	TO	to	to	to	N	O
severe	JJ	severe	severe	sever	N	O
intensity	NN	intensity	intensity	intens	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
either	DT	either	either	either	N	O
treatment	NN	treatment	treatment	treatment	N	O
arm	NN	arm	arm	arm	N	O
in	IN	in	in	in	N	O
SPRING	NN	spring	spring	spring	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
and	CC	and	and	and	N	O
SINGLE	NNP	single	single	singl	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
provided	VBN	provided	provided	provid	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Side	NNP	side	side	side	N	O
-	:	-	-	-	N	O
by	IN	by	by	by	N	O
-	:	-	-	-	N	O
side	NN	side	side	side	N	O
tabulation	NN	tabulation	tabulation	tabul	N	O
is	VBZ	is	is	is	N	O
to	TO	to	to	to	N	O
simplify	VB	simplify	simplify	simplifi	N	O
presentation	NN	presentation	presentation	present	N	O
;	:	;	;	;	N	O
direct	JJ	direct	direct	direct	N	O
comparisons	NNS	comparisons	comparison	comparison	N	O
across	IN	across	across	across	N	O
trials	NNS	trials	trial	trial	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
made	VBN	made	made	made	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
differing	VBG	differing	differing	differ	N	O
trial	NN	trial	trial	trial	N	O
designs	NNS	designs	design	design	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	JJ	emergent	emergent	emerg	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Drug	NNP	drug	drug	drug	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
at	IN	at	at	at	N	O
Least	NNP	least	least	least	N	O
Moderate	NNP	moderate	moderate	moder	N	O
Intensity	NNP	intensity	intensity	intens	N	O
(	(	(	(	(	N	O
Grades	NNP	grades	grade	grade	N	O
2	CD	2	2	2	N	O
to	TO	to	to	to	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
Least	JJS	least	least	least	N	O
2%	CD	2%	2%	2%	N	O
Frequency	NNP	frequency	frequency	frequenc	N	O
in	IN	in	in	in	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
naive	JJ	naive	naive	naiv	N	O
Subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
SPRING	NNP	spring	spring	spring	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
and	CC	and	and	and	N	O
SINGLE	NNP	single	single	singl	N	O
Trials	NNP	trials	trial	trial	N	O
(	(	(	(	(	N	O
Week	NNP	week	week	week	N	O
96	CD	96	96	96	N	O
Analysis	NN	analysis	analysis	analysi	N	O
)	)	)	)	)	N	O

System	NNP	system	system	system	N	O
Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
SPRING	NNP	spring	spring	spring	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
SINGLE	NN	single	single	singl	N	O

TIVICAY	$	tivicay	tivicay	tivicay	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
Once	NNP	once	once	onc	N	O
Daily	NNP	daily	daily	daili	N	O
2	CD	2	2	2	N	O
NRTIs	NNP	nrtis	nrti	nrti	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
403	CD	403	403	403	N	O
)	)	)	)	)	N	O
Raltegravir	NNP	raltegravir	raltegravir	raltegravir	N	O
400	CD	400	400	400	N	O
mg	NN	mg	mg	mg	N	O
Twice	NNP	twice	twice	twice	N	O
Daily	NNP	daily	daily	daili	N	O
2	CD	2	2	2	N	O
NRTIs	NNP	nrtis	nrti	nrti	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
405	CD	405	405	405	N	O
)	)	)	)	)	N	O
TIVICAY	$	tivicay	tivicay	tivicay	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
EPZICOM	NNP	epzicom	epzicom	epzicom	N	O
Once	NNP	once	once	onc	N	O
Daily	NNP	daily	daily	daili	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
414	CD	414	414	414	N	O
)	)	)	)	)	N	O
ATRIPLA	NNP	atripla	atripla	atripla	N	O
Once	NNP	once	once	onc	N	O
Daily	NNP	daily	daily	daili	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
419	CD	419	419	419	N	O
)	)	)	)	)	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O
3%	CD	3%	3%	3%	N	O
2%	CD	2%	2%	2%	N	O

Depression	NNP	depression	depression	depress	Y	B-AdverseReaction
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O
2%	CD	2%	2%	2%	N	O

Abnormal	JJ	abnormal	abnormal	abnorm	N	B-AdverseReaction
dreams	VBZ	dreams	dream	dream	N	I-AdverseReaction
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O
2%	CD	2%	2%	2%	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
System	NN	system	system	system	N	O

Dizziness	NNP	dizziness	dizziness	dizzi	Y	B-AdverseReaction
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O
5%	CD	5%	5%	5%	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O
2%	CD	2%	2%	2%	N	O
2%	CD	2%	2%	2%	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O
3%	CD	3%	3%	3%	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O
2%	CD	2%	2%	2%	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Subcutaneous	NNP	subcutaneous	subcutaneous	subcutan	N	O
Tissue	NNP	tissue	tissue	tissu	N	O

Rasha	NNP	rasha	rasha	rasha	N	B-AdverseReaction
0	CD	0	0	0	N	O
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O
6%	CD	6%	6%	6%	N	O

General	NNP	general	general	gener	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O
2%	CD	2%	2%	2%	N	O
2%	CD	2%	2%	2%	N	O

Ear	NN	ear	ear	ear	N	O
and	CC	and	and	and	N	O
Labyrinth	NNP	labyrinth	labyrinth	labyrinth	N	O

Vertigo	NNP	vertigo	vertigo	vertigo	Y	B-AdverseReaction
0	CD	0	0	0	N	O
1%	CD	1%	1%	1%	N	O
0	CD	0	0	0	N	O
2%	CD	2%	2%	2%	N	O

a	DT	a	a	a	N	O
Includes	NNP	includes	includes	includ	N	O
pooled	VBD	pooled	pooled	pool	N	O
terms	NNS	terms	term	term	N	O
:	:	:	:	:	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
generalized	VBD	generalized	generalized	gener	N	I-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
macular	NN	macular	macular	macular	N	I-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
maculo	SYM	maculo	maculo	maculo	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
papular	NN	papular	papular	papular	N	I-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
pruritic	NN	pruritic	pruritic	prurit	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
drug	NN	drug	drug	drug	N	B-AdverseReaction
eruption	NN	eruption	eruption	erupt	Y	I-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O

addition	NN	addition	addition	addit	N	O
,	,	,	,	,	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
1	CD	1	1	1	N	I-Severity
insomnia	NN	insomnia	insomnia	insomnia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
and	CC	and	and	and	N	O
raltegravir	NN	raltegravir	raltegravir	raltegravir	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
SPRING	NNP	spring	spring	spring	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
;	:	;	;	;	N	O
whereas	NNS	whereas	whereas	wherea	N	O
in	IN	in	in	in	N	O
SINGLE	NNP	single	single	singl	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
were	VBD	were	were	were	N	O
7%	CD	7%	7%	7%	N	O
and	CC	and	and	and	N	O
4%	CD	4%	4%	4%	N	O
for	IN	for	for	for	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
and	CC	and	and	and	N	O
ATRIPLA	NNP	atripla	atripla	atripla	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	O
treatment	NN	treatment	treatment	treatment	N	O
limiting	NN	limiting	limiting	limit	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
multicenter	NN	multicenter	multicenter	multicent	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
FLAMINGO	NNP	flamingo	flamingo	flamingo	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
243	CD	243	243	243	N	O
subjects	NNS	subjects	subject	subject	N	O
received	VBD	received	received	receiv	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
versus	NN	versus	versus	versu	N	O
242	CD	242	242	242	N	O
subjects	NNS	subjects	subject	subject	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
darunavir	RB	darunavir	darunavir	darunavir	N	O
800	CD	800	800	800	N	O
mg	NNS	mg	mg	mg	N	O
ritonavir	VBP	ritonavir	ritonavir	ritonavir	N	O
100	CD	100	100	100	N	O
mg	NNS	mg	mg	mg	N	O
once	RB	once	once	onc	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
both	DT	both	both	both	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
investigator	NN	investigator	investigator	investig	N	O
-	:	-	-	-	N	O
selected	VBN	selected	selected	select	N	O
NRTI	NNP	nrti	nrti	nrti	N	O
background	IN	background	background	background	N	O
regimen	NNS	regimen	regimen	regimen	N	O
(	(	(	(	(	N	O
either	CC	either	either	either	N	O
EPZICOM	NNP	epzicom	epzicom	epzicom	N	O
or	CC	or	or	or	N	O
TRUVADA	NNP	truvada	truvada	truvada	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
484	CD	484	484	484	N	O
subjects	NNS	subjects	subject	subject	N	O
included	VBN	included	included	includ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
and	CC	and	and	and	N	O
safety	NN	safety	safety	safeti	N	O
analyses	NNS	analyses	analysis	analys	N	O
.	.	.	.	.	N	O

Through	IN	through	through	through	N	O
48	CD	48	48	48	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
were	VBD	were	were	were	N	O
2%	CD	2%	2%	2%	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
and	CC	and	and	and	N	O
4%	CD	4%	4%	4%	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
darunavir	NN	darunavir	darunavir	darunavir	N	O
ritonavir	NN	ritonavir	ritonavir	ritonavir	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
ADRs	NNP	adrs	adrs	adr	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
FLAMINGO	NNP	flamingo	flamingo	flamingo	N	O
were	VBD	were	were	were	N	O
generally	RB	generally	generally	gener	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
those	DT	those	those	those	N	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
SPRING	NNP	spring	spring	spring	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
and	CC	and	and	and	N	O
SINGLE	NNP	single	single	singl	N	O
.	.	.	.	.	N	O

Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
experienced	VBD	experienced	experienced	experienc	N	O
,	,	,	,	,	N	O
Integrase	NNP	integrase	integrase	integras	N	O
Strand	NNP	strand	strand	strand	N	O
Transfer	NNP	transfer	transfer	transfer	N	O
Inhibitor	NNP	inhibitor	inhibitor	inhibitor	N	O
-	:	-	-	-	N	O
naive	JJ	naive	naive	naiv	N	O
Subjects	NNS	subjects	subject	subject	N	O
:	:	:	:	:	N	O
In	IN	in	in	in	N	O
an	DT	an	an	an	N	O
international	JJ	international	international	intern	N	O
,	,	,	,	,	N	O
multicenter	NN	multicenter	multicenter	multicent	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
ING111762	NNP	ing111762	ing111762	ing111762	N	O
,	,	,	,	,	N	O
SAILING	NNP	sailing	sailing	sail	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
719	CD	719	719	719	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
infected	VBN	infected	infected	infect	N	O
,	,	,	,	,	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
experienced	JJ	experienced	experienced	experienc	N	O
adults	NNS	adults	adult	adult	N	O
were	VBD	were	were	were	N	O
randomized	VBN	randomized	randomized	random	N	O
and	CC	and	and	and	N	O
received	VBN	received	received	receiv	N	O
either	RB	either	either	either	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
or	CC	or	or	or	N	O
raltegravir	JJ	raltegravir	raltegravir	raltegravir	N	O
400	CD	400	400	400	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
with	IN	with	with	with	N	O
investigator	NN	investigator	investigator	investig	N	O
-	:	-	-	-	N	O
selected	VBN	selected	selected	select	N	O
background	IN	background	background	background	N	O
regimen	NNS	regimen	regimen	regimen	N	O
consisting	VBG	consisting	consisting	consist	N	O
of	IN	of	of	of	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
2	CD	2	2	2	N	O
agents	NNS	agents	agent	agent	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
fully	RB	fully	fully	fulli	N	O
active	JJ	active	active	activ	N	O
agent	NN	agent	agent	agent	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
48	CD	48	48	48	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
were	VBD	were	were	were	N	O
3%	CD	3%	3%	3%	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
background	IN	background	background	background	N	O
regimen	NNS	regimen	regimen	regimen	N	O
and	CC	and	and	and	N	O
4%	CD	4%	4%	4%	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
raltegravir	NN	raltegravir	raltegravir	raltegravir	N	O
400	CD	400	400	400	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
background	IN	background	background	background	N	O
regimen	NNS	regimen	regimen	regimen	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
only	JJ	only	only	onli	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	NN	emergent	emergent	emerg	N	O
ADR	NNP	adr	adr	adr	N	O
of	IN	of	of	of	N	O
moderate	JJ	moderate	moderate	moder	N	B-Severity
to	TO	to	to	to	N	O
severe	JJ	severe	severe	sever	N	B-Severity
intensity	NN	intensity	intensity	intens	N	O
with	IN	with	with	with	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2%	CD	2%	2%	2%	N	O
frequency	NN	frequency	frequency	frequenc	N	O
in	IN	in	in	in	N	O
either	DT	either	either	either	N	O
treatment	NN	treatment	treatment	treatment	N	O
group	NN	group	group	group	N	O
was	VBD	was	wa	wa	N	O
diarrhea	RB	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
of	IN	of	of	of	N	O
354	CD	354	354	354	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
background	IN	background	background	background	N	O
regimen	NNS	regimen	regimen	regimen	N	O
and	CC	and	and	and	N	O
1%	CD	1%	1%	1%	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
of	IN	of	of	of	N	O
361	CD	361	361	361	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
raltegravir	NN	raltegravir	raltegravir	raltegravir	N	O
400	CD	400	400	400	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
background	IN	background	background	background	N	O
regimen	NNS	regimen	regimen	regimen	N	O
.	.	.	.	.	N	O

Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
experienced	VBD	experienced	experienced	experienc	N	O
,	,	,	,	,	N	O
Integrase	NNP	integrase	integrase	integras	N	O
Strand	NNP	strand	strand	strand	N	O
Transfer	NNP	transfer	transfer	transfer	N	O
Inhibitor	NNP	inhibitor	inhibitor	inhibitor	N	O
-	:	-	-	-	N	O
experienced	JJ	experienced	experienced	experienc	N	O
Subjects	NNS	subjects	subject	subject	N	O
:	:	:	:	:	N	O
In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
multicenter	NN	multicenter	multicenter	multicent	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
,	,	,	,	,	N	O
single	JJ	single	single	singl	N	O
-	:	-	-	-	N	O
arm	NN	arm	arm	arm	N	O
trial	NN	trial	trial	trial	N	O
(	(	(	(	(	N	O
ING112574	NNP	ing112574	ing112574	ing112574	N	O
,	,	,	,	,	N	O
VIKING	NNP	viking	viking	vike	N	O
-	:	-	-	-	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
183	CD	183	183	183	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
infected	VBN	infected	infected	infect	N	O
,	,	,	,	,	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
experienced	JJ	experienced	experienced	experienc	N	O
adults	NNS	adults	adult	adult	N	O
with	IN	with	with	with	N	O
virological	JJ	virological	virological	virolog	N	O
failure	NN	failure	failure	failur	N	O
and	CC	and	and	and	N	O
current	JJ	current	current	current	N	O
or	CC	or	or	or	N	O
historical	JJ	historical	historical	histor	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
raltegravir	NN	raltegravir	raltegravir	raltegravir	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
elvitegravir	VB	elvitegravir	elvitegravir	elvitegravir	N	O
resistance	NN	resistance	resistance	resist	N	O
received	VBD	received	received	receiv	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
current	JJ	current	current	current	N	O
failing	NN	failing	failing	fail	N	O
background	NN	background	background	background	N	O
regimen	NNS	regimen	regimen	regimen	N	O
for	IN	for	for	for	N	O
7	CD	7	7	7	N	O
days	NNS	days	day	day	N	O
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
optimized	JJ	optimized	optimized	optim	N	O
background	NN	background	background	background	N	O
therapy	NN	therapy	therapy	therapi	N	O
from	IN	from	from	from	N	O
Day	NNP	day	day	day	N	O
8	CD	8	8	8	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
was	VBD	was	wa	wa	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
at	IN	at	at	at	N	O
Week	NNP	week	week	week	N	O
48	CD	48	48	48	N	O
.	.	.	.	.	N	O

Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	NN	emergent	emergent	emerg	N	O
ADRs	NNP	adrs	adrs	adr	N	O
in	IN	in	in	in	N	O
VIKING	NNP	viking	viking	vike	N	O
-	:	-	-	-	N	O
3	CD	3	3	3	N	O
were	VBD	were	were	were	N	O
generally	RB	generally	generally	gener	N	O
similar	JJ	similar	similar	similar	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
observations	NNS	observations	observation	observ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
50	CD	50	50	50	N	O
-	:	-	-	-	N	O
mg	NN	mg	mg	mg	N	O
once	RB	once	once	onc	N	O
-	:	-	-	-	N	O
daily	JJ	daily	daily	daili	N	O
dose	NN	dose	dose	dose	N	O
in	IN	in	in	in	N	O
adult	NN	adult	adult	adult	N	O
Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Less	NNP	less	le	less	N	O
Common	NNP	common	common	common	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Observed	NNP	observed	observed	observ	N	O
in	IN	in	in	in	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
naive	JJ	naive	naive	naiv	N	O
and	CC	and	and	and	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
experienced	VBD	experienced	experienced	experienc	N	O
Trials	NNS	trials	trial	trial	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
ADRs	NNP	adrs	adrs	adr	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
naive	JJ	naive	naive	naiv	N	O
or	CC	or	or	or	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
experienced	JJ	experienced	experienced	experienc	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
combination	NN	combination	combination	combin	N	O
regimen	NNS	regimen	regimen	regimen	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
one	CD	one	one	one	N	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
included	VBN	included	included	includ	N	O
because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
their	PRP$	their	their	their	N	O
seriousness	NN	seriousness	seriousness	serious	N	O
and	CC	and	and	and	N	O
assessment	NN	assessment	assessment	assess	N	O
of	IN	of	of	of	N	O
potential	JJ	potential	potential	potenti	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
.	.	.	.	.	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
,	,	,	,	,	N	O
flatulence	NN	flatulence	flatulence	flatul	Y	B-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
abdominal	JJ	abdominal	abdominal	abdomin	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
.	.	.	.	.	N	O

Hepatobiliary	JJ	hepatobiliary	hepatobiliary	hepatobiliari	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Hepatitis	NN	hepatitis	hepatitis	hepat	Y	B-AdverseReaction
.	.	.	.	.	N	O

Musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Myositis	NN	myositis	myositis	myositi	Y	B-AdverseReaction
.	.	.	.	.	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Suicidal	NNP	suicidal	suicidal	suicid	N	B-AdverseReaction
ideation	NN	ideation	ideation	ideat	N	I-AdverseReaction
,	,	,	,	,	N	O
attempt	NN	attempt	attempt	attempt	N	I-AdverseReaction
,	,	,	,	,	N	O
behavior	NN	behavior	behavior	behavior	N	I-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
completion	NN	completion	completion	complet	N	I-AdverseReaction
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
primarily	RB	primarily	primarily	primarili	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
pre	NN	pre	pre	pre	N	O
-	:	-	-	-	N	O
existing	VBG	existing	existing	exist	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
depression	NN	depression	depression	depress	Y	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
illness	NN	illness	illness	ill	N	O
.	.	.	.	.	N	O

Renal	NNP	renal	renal	renal	N	O
and	CC	and	and	and	N	O
Urinary	JJ	urinary	urinary	urinari	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Renal	JJ	renal	renal	renal	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
.	.	.	.	.	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Subcutaneous	NNP	subcutaneous	subcutaneous	subcutan	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
.	.	.	.	.	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O
Abnormalities	NNS	abnormalities	abnormality	abnorm	N	O

Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
naive	JJ	naive	naive	naiv	N	O
Subjects	NNS	subjects	subject	subject	N	O
:	:	:	:	:	N	O
Selected	VBN	selected	selected	select	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
(	(	(	(	(	N	O
Grades	NNP	grades	grade	grade	N	O
2	CD	2	2	2	N	O
to	TO	to	to	to	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
worsening	VBG	worsening	worsening	worsen	N	O
grade	NN	grade	grade	grade	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
representing	VBG	representing	representing	repres	N	O
the	DT	the	the	the	N	O
worst	JJS	worst	worst	worst	N	O
-	:	-	-	-	N	O
grade	NN	grade	grade	grade	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
change	NN	change	change	chang	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
observed	VBN	observed	observed	observ	N	O
for	IN	for	for	for	N	O
selected	VBN	selected	selected	select	N	O
lipid	JJ	lipid	lipid	lipid	N	O
values	NNS	values	value	valu	N	O
is	VBZ	is	is	is	N	O
presented	VBN	presented	presented	present	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
.	.	.	.	.	N	O

Side	NNP	side	side	side	N	O
-	:	-	-	-	N	O
by	IN	by	by	by	N	O
-	:	-	-	-	N	O
side	NN	side	side	side	N	O
tabulation	NN	tabulation	tabulation	tabul	N	O
is	VBZ	is	is	is	N	O
to	TO	to	to	to	N	O
simplify	VB	simplify	simplify	simplifi	N	O
presentation	NN	presentation	presentation	present	N	O
;	:	;	;	;	N	O
direct	JJ	direct	direct	direct	N	O
comparisons	NNS	comparisons	comparison	comparison	N	O
across	IN	across	across	across	N	O
trials	NNS	trials	trial	trial	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
made	VBN	made	made	made	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
differing	VBG	differing	differing	differ	N	O
trial	NN	trial	trial	trial	N	O
designs	NNS	designs	design	design	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

Selected	VBN	selected	selected	select	N	O
Laboratory	JJ	laboratory	laboratory	laboratori	N	O
Abnormalities	NNP	abnormalities	abnormality	abnorm	N	O
(	(	(	(	(	N	O
Grades	NNP	grades	grade	grade	N	O
2	CD	2	2	2	N	O
to	TO	to	to	to	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
naive	JJ	naive	naive	naiv	N	O
Subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
SPRING	NNP	spring	spring	spring	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
and	CC	and	and	and	N	O
SINGLE	NNP	single	single	singl	N	O
Trials	NNP	trials	trial	trial	N	O
(	(	(	(	(	N	O
Week	NNP	week	week	week	N	O
96	CD	96	96	96	N	O
Analysis	NN	analysis	analysis	analysi	N	O
)	)	)	)	)	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O
Parameter	NNP	parameter	parameter	paramet	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
SPRING	NNP	spring	spring	spring	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
SINGLE	NN	single	single	singl	N	O

TIVICAY	$	tivicay	tivicay	tivicay	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
Once	NNP	once	once	onc	N	O
Daily	NNP	daily	daily	daili	N	O
2	CD	2	2	2	N	O
NRTIs	NNP	nrtis	nrti	nrti	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
403	CD	403	403	403	N	O
)	)	)	)	)	N	O
Raltegravir	NNP	raltegravir	raltegravir	raltegravir	N	O
400	CD	400	400	400	N	O
mg	NN	mg	mg	mg	N	O
Twice	NNP	twice	twice	twice	N	O
Daily	NNP	daily	daily	daili	N	O
2	CD	2	2	2	N	O
NRTIs	NNP	nrtis	nrti	nrti	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
405	CD	405	405	405	N	O
)	)	)	)	)	N	O
TIVICAY	$	tivicay	tivicay	tivicay	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
EPZICOM	NNP	epzicom	epzicom	epzicom	N	O
Once	NNP	once	once	onc	N	O
Daily	NNP	daily	daily	daili	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
414	CD	414	414	414	N	O
)	)	)	)	)	N	O
ATRIPLA	NNP	atripla	atripla	atripla	N	O
Once	NNP	once	once	onc	N	O
Daily	NNP	daily	daily	daili	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
419	CD	419	419	419	N	O
)	)	)	)	)	N	O

ALT	NN	alt	alt	alt	N	O

4%	CD	4%	4%	4%	N	O
4%	CD	4%	4%	4%	N	O
2%	CD	2%	2%	2%	N	O
5%	CD	5%	5%	5%	N	O

2%	CD	2%	2%	2%	N	O
2%	CD	2%	2%	2%	N	O
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O

AST	NN	ast	ast	ast	N	O

5%	CD	5%	5%	5%	N	O
3%	CD	3%	3%	3%	N	O
3%	CD	3%	3%	3%	N	O
3%	CD	3%	3%	3%	N	O

3%	CD	3%	3%	3%	N	O
2%	CD	2%	2%	2%	N	O
1%	CD	1%	1%	1%	N	O
3%	CD	3%	3%	3%	N	O

3%	CD	3%	3%	3%	N	O

2%	CD	2%	2%	2%	N	O
1%	CD	1%	1%	1%	N	O
0	CD	0	0	0	N	O

1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O
1%	CD	1%	1%	1%	N	O
0	CD	0	0	0	N	O

Creatine	NNP	creatine	creatine	creatin	Y	O
kinase	NN	kinase	kinase	kinas	N	O

2%	CD	2%	2%	2%	N	O
5%	CD	5%	5%	5%	N	O
4%	CD	4%	4%	4%	N	O
1%	CD	1%	1%	1%	N	O

7%	CD	7%	7%	7%	N	O
4%	CD	4%	4%	4%	N	O
5%	CD	5%	5%	5%	N	O
7%	CD	7%	7%	7%	N	O

Hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction

6%	CD	6%	6%	6%	N	O
6%	CD	6%	6%	6%	N	O
7%	CD	7%	7%	7%	N	O
5%	CD	5%	5%	5%	N	O

1%	CD	1%	1%	1%	N	O
2%	CD	2%	2%	2%	N	O
2%	CD	2%	2%	2%	N	O
1%	CD	1%	1%	1%	N	O

Lipase	NN	lipase	lipase	lipas	Y	O

7%	CD	7%	7%	7%	N	O
7%	CD	7%	7%	7%	N	O
9%	CD	9%	9%	9%	N	O
9%	CD	9%	9%	9%	N	O

2%	CD	2%	2%	2%	N	O
5%	CD	5%	5%	5%	N	O
4%	CD	4%	4%	4%	N	O
3%	CD	3%	3%	3%	N	O

Total	JJ	total	total	total	N	O
neutrophils	NNS	neutrophils	neutrophil	neutrophil	Y	O

4%	CD	4%	4%	4%	N	O
3%	CD	3%	3%	3%	N	O
3%	CD	3%	3%	3%	N	O
5%	CD	5%	5%	5%	N	O

2%	CD	2%	2%	2%	N	O
2%	CD	2%	2%	2%	N	O
2%	CD	2%	2%	2%	N	O
3%	CD	3%	3%	3%	N	O

ULN	NNP	uln	uln	uln	N	O
Upper	NNP	upper	upper	upper	N	O
limit	NN	limit	limit	limit	N	O
of	IN	of	of	of	N	O
normal	JJ	normal	normal	normal	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

4	CD	4	4	4	N	O
.	.	.	.	.	N	O

Mean	JJ	mean	mean	mean	N	O
Change	NNP	change	change	chang	N	O
from	IN	from	from	from	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
in	IN	in	in	in	N	O
Fasted	NNP	fasted	fasted	fast	N	O
Lipid	NNP	lipid	lipid	lipid	N	O
Values	NNP	values	value	valu	N	O
in	IN	in	in	in	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
naive	JJ	naive	naive	naiv	N	O
Subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
SPRING	NNP	spring	spring	spring	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
and	CC	and	and	and	N	O
SINGLE	NNP	single	single	singl	N	O
Trials	NNP	trials	trial	trial	N	O
(	(	(	(	(	N	O
Week	NNP	week	week	week	N	O
96	CD	96	96	96	N	O
Analysisa	NNP	analysisa	analysisa	analysisa	N	O
)	)	)	)	)	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O
Parameter	NNP	parameter	parameter	paramet	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
SPRING	NNP	spring	spring	spring	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
SINGLE	NN	single	single	singl	N	O

TIVICAY	$	tivicay	tivicay	tivicay	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
Once	NNP	once	once	onc	N	O
Daily	NNP	daily	daily	daili	N	O
2	CD	2	2	2	N	O
NRTIs	NNP	nrtis	nrti	nrti	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
403	CD	403	403	403	N	O
)	)	)	)	)	N	O
Raltegravir	NNP	raltegravir	raltegravir	raltegravir	N	O
400	CD	400	400	400	N	O
mg	NN	mg	mg	mg	N	O
Twice	NNP	twice	twice	twice	N	O
Daily	NNP	daily	daily	daili	N	O
2	CD	2	2	2	N	O
NRTIs	NNP	nrtis	nrti	nrti	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
405	CD	405	405	405	N	O
)	)	)	)	)	N	O
TIVICAY	$	tivicay	tivicay	tivicay	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
EPZICOM	NNP	epzicom	epzicom	epzicom	N	O
Once	NNP	once	once	onc	N	O
Daily	NNP	daily	daily	daili	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
414	CD	414	414	414	N	O
)	)	)	)	)	N	O
ATRIPLA	NNP	atripla	atripla	atripla	N	O
Once	NNP	once	once	onc	N	O
Daily	NNP	daily	daily	daili	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
419	CD	419	419	419	N	O
)	)	)	)	)	N	O

Cholesterol	NNP	cholesterol	cholesterol	cholesterol	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
8.1	CD	8.1	8.1	8.1	N	O
10.1	CD	10.1	10.1	10.1	N	O
23.2	CD	23.2	23.2	23.2	N	O
28.0	CD	28.0	28.0	28.0	N	O

HDL	NNP	hdl	hdl	hdl	Y	O
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	O
(	(	(	(	(	N	O
mg	JJ	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
2.0	CD	2.0	2.0	2.0	N	O
2.3	CD	2.3	2.3	2.3	N	O
5.2	CD	5.2	5.2	5.2	N	O
7.4	CD	7.4	7.4	7.4	N	O

LDL	NNP	ldl	ldl	ldl	Y	O
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	O
(	(	(	(	(	N	O
mg	JJ	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
5.1	CD	5.1	5.1	5.1	N	O
6.1	CD	6.1	6.1	6.1	N	O
14.5	CD	14.5	14.5	14.5	N	O
18.0	CD	18.0	18.0	18.0	N	O

Triglycerides	NNP	triglycerides	triglyceride	triglycerid	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
6.7	CD	6.7	6.7	6.7	N	O
6.6	CD	6.6	6.6	6.6	N	O
17.2	CD	17.2	17.2	17.2	N	O
17.4	CD	17.4	17.4	17.4	N	O

a	DT	a	a	a	N	O
Subjects	NNS	subjects	subject	subject	N	O
on	IN	on	on	on	N	O
lipid	JJ	lipid	lipid	lipid	N	O
-	:	-	-	-	N	O
lowering	VBG	lowering	lowering	lower	N	O
agents	NNS	agents	agent	agent	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
were	VBD	were	were	were	N	O
excluded	VBN	excluded	excluded	exclud	N	O
from	IN	from	from	from	N	O
these	DT	these	these	these	N	O
analyses	NNS	analyses	analysis	analys	N	O
(	(	(	(	(	N	O
19	CD	19	19	19	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
each	DT	each	each	each	N	O
arm	NN	arm	arm	arm	N	O
in	IN	in	in	in	N	O
SPRING	NN	spring	spring	spring	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
SINGLE	NNP	single	single	singl	N	O
:	:	:	:	:	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
n	CC	n	n	n	N	O
30	CD	30	30	30	N	O
and	CC	and	and	and	N	O
ATRIPLA	NNP	atripla	atripla	atripla	N	O
n	RB	n	n	n	N	O
27	CD	27	27	27	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Seventy	NNP	seventy	seventy	seventi	N	O
-	:	-	-	-	N	O
seven	CD	seven	seven	seven	N	O
subjects	NNS	subjects	subject	subject	N	O
initiated	VBD	initiated	initiated	initi	N	O
a	DT	a	a	a	N	O
lipid	JJ	lipid	lipid	lipid	N	O
-	:	-	-	-	N	O
lowering	VBG	lowering	lowering	lower	N	O
agent	NN	agent	agent	agent	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
baseline	NN	baseline	baseline	baselin	N	O
;	:	;	;	;	N	O
their	PRP$	their	their	their	N	O
last	JJ	last	last	last	N	O
fasted	VBN	fasted	fasted	fast	N	O
on	IN	on	on	on	N	O
-	:	-	-	-	N	O
treatment	NN	treatment	treatment	treatment	N	O
values	NNS	values	value	valu	N	O
(	(	(	(	(	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
starting	VBG	starting	starting	start	N	O
the	DT	the	the	the	N	O
agent	NN	agent	agent	agent	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
used	VBN	used	used	use	N	O
regardless	RB	regardless	regardless	regardless	N	O
if	IN	if	if	if	N	O
they	PRP	they	they	they	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
the	DT	the	the	the	N	O
agent	NN	agent	agent	agent	N	O
(	(	(	(	(	N	O
SPRING	NNP	spring	spring	spring	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
n	RB	n	n	n	N	O
9	CD	9	9	9	N	O
,	,	,	,	,	N	O
raltegravir	NN	raltegravir	raltegravir	raltegravir	N	O
n	RB	n	n	n	N	O
13	CD	13	13	13	N	O
;	:	;	;	;	N	O
SINGLE	NNP	single	single	singl	N	O
:	:	:	:	:	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
n	CC	n	n	n	N	O
25	CD	25	25	25	N	O
and	CC	and	and	and	N	O
ATRIPLA	NNP	atripla	atripla	atripla	N	O
:	:	:	:	:	N	O
n	RB	n	n	n	N	O
30	CD	30	30	30	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O

abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
FLAMINGO	NNP	flamingo	flamingo	flamingo	N	O
trial	NN	trial	trial	trial	N	O
were	VBD	were	were	were	N	O
generally	RB	generally	generally	gener	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
observations	NNS	observations	observation	observ	N	O
in	IN	in	in	in	N	O
SPRING	NNP	spring	spring	spring	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
and	CC	and	and	and	N	O
SINGLE	NNP	single	single	singl	N	O
.	.	.	.	.	N	O

Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
experienced	VBD	experienced	experienced	experienc	N	O
,	,	,	,	,	N	O
Integrase	NNP	integrase	integrase	integras	N	O
Strand	NNP	strand	strand	strand	N	O
Transfer	NNP	transfer	transfer	transfer	N	O
Inhibitor	NNP	inhibitor	inhibitor	inhibitor	N	O
-	:	-	-	-	N	O
naive	JJ	naive	naive	naiv	N	O
Subjects	NNS	subjects	subject	subject	N	O
:	:	:	:	:	N	O
Laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
SAILING	NN	sailing	sailing	sail	N	O
were	VBD	were	were	were	N	O
generally	RB	generally	generally	gener	N	O
similar	JJ	similar	similar	similar	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
observations	NNS	observations	observation	observ	N	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
naive	JJ	naive	naive	naiv	N	O
(	(	(	(	(	N	O
SPRING	NNP	spring	spring	spring	N	O
-	:	-	-	-	N	O
2	CD	2	2	2	N	O
and	CC	and	and	and	N	O
SINGLE	NNP	single	single	singl	N	O
)	)	)	)	)	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
experienced	VBD	experienced	experienced	experienc	N	O
,	,	,	,	,	N	O
Integrase	NNP	integrase	integrase	integras	N	O
Strand	NNP	strand	strand	strand	N	O
Transfer	NNP	transfer	transfer	transfer	N	O
Inhibitor	NNP	inhibitor	inhibitor	inhibitor	N	O
-	:	-	-	-	N	O
experienced	JJ	experienced	experienced	experienc	N	O
Subjects	NNS	subjects	subject	subject	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	JJ	emergent	emergent	emerg	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
(	(	(	(	(	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
5%	CD	5%	5%	5%	N	O
for	IN	for	for	for	N	O
Grades	NNP	grades	grade	grade	N	O
2	CD	2	2	2	N	O
to	TO	to	to	to	N	O
4	CD	4	4	4	N	O
combined	VBN	combined	combined	combin	N	O
)	)	)	)	)	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
VIKING	NNP	viking	viking	vike	N	O
-	:	-	-	-	N	O
3	CD	3	3	3	N	O
at	IN	at	at	at	N	O
Week	JJ	week	week	week	N	O
48	CD	48	48	48	N	O
were	VBD	were	were	were	N	O
elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
AST	NNP	ast	ast	ast	N	O
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
cholesterol	NN	cholesterol	cholesterol	cholesterol	Y	I-AdverseReaction
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
creatine	JJ	creatine	creatine	creatin	Y	I-AdverseReaction
kinase	NN	kinase	kinase	kinas	N	I-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
(	(	(	(	(	N	O
14%	CD	14%	14%	14%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
lipase	NN	lipase	lipase	lipas	Y	I-AdverseReaction
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Two	CD	two	two	two	N	O
percent	NN	percent	percent	percent	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
of	IN	of	of	of	N	O
183	CD	183	183	183	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
to	TO	to	to	to	N	O
4	CD	4	4	4	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	NN	emergent	emergent	emerg	N	O
hematology	NN	hematology	hematology	hematolog	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormality	NN	abnormality	abnormality	abnorm	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
[	RB	[	[	[	N	O
3	CD	3	3	3	N	O
of	IN	of	of	of	N	O
183	CD	183	183	183	N	O
])	NNS	])	])	])	N	O
being	VBG	being	being	be	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequently	RB	frequently	frequently	frequent	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

Hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
Hepatitis	NNP	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
Virus	NNP	virus	virus	viru	N	O
Co	NNP	co	co	co	N	O
-	:	-	-	-	N	O
infection	NN	infection	infection	infect	Y	O
:	:	:	:	:	N	O
In	IN	in	in	in	N	O
Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
C	NNP	c	c	c	N	O
virus	VBP	virus	virus	viru	N	O
co	SYM	co	co	co	N	O
-	:	-	-	-	N	O
infection	NN	infection	infection	infect	Y	O
were	VBD	were	were	were	N	O
permitted	VBN	permitted	permitted	permit	N	O
to	TO	to	to	to	N	O
enroll	VB	enroll	enroll	enrol	N	O
provided	VBN	provided	provided	provid	N	O
that	IN	that	that	that	N	O
baseline	NN	baseline	baseline	baselin	N	O
liver	RB	liver	liver	liver	N	O
chemistry	NN	chemistry	chemistry	chemistri	N	O
tests	NNS	tests	test	test	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
exceed	VB	exceed	exceed	exceed	N	O
5	CD	5	5	5	N	O
times	NNS	times	time	time	N	O
the	DT	the	the	the	N	O
upper	JJ	upper	upper	upper	N	O
limit	NN	limit	limit	limit	N	O
of	IN	of	of	of	N	O
normal	JJ	normal	normal	normal	N	O
.	.	.	.	.	N	O

Overall	JJ	overall	overall	overal	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
profile	NN	profile	profile	profil	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
C	NNP	c	c	c	N	O
virus	VBP	virus	virus	viru	N	O
co	SYM	co	co	co	N	O
-	:	-	-	-	N	O
infection	NN	infection	infection	infect	Y	O
was	VBD	was	wa	wa	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
that	DT	that	that	that	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
without	IN	without	without	without	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
or	CC	or	or	or	N	O
C	NNP	c	c	c	N	O
co	SYM	co	co	co	N	O
-	:	-	-	-	N	O
infection	NN	infection	infection	infect	Y	O
,	,	,	,	,	N	O
although	IN	although	although	although	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
of	IN	of	of	of	N	O
AST	NNP	ast	ast	ast	N	B-AdverseReaction
and	CC	and	and	and	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
were	VBD	were	were	were	N	O
higher	JJR	higher	higher	higher	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
subgroup	NN	subgroup	subgroup	subgroup	N	O
with	IN	with	with	with	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
C	NNP	c	c	c	N	O
virus	VBP	virus	virus	viru	N	O
co	SYM	co	co	co	N	O
-	:	-	-	-	N	O
infection	NN	infection	infection	infect	Y	O
for	IN	for	for	for	N	O
all	DT	all	all	all	N	O
treatment	NN	treatment	treatment	treatment	N	O
groups	NNS	groups	group	group	N	O
.	.	.	.	.	N	O

Grades	NNS	grades	grade	grade	N	B-Severity
2	CD	2	2	2	N	I-Severity
to	TO	to	to	to	N	I-Severity
4	CD	4	4	4	N	I-Severity
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
in	IN	in	in	in	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
C	NNP	c	c	c	N	O
co	SYM	co	co	co	N	O
-	:	-	-	-	N	O
infected	VBN	infected	infected	infect	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
HIV	NNP	hiv	hiv	hiv	N	O
mono	FW	mono	mono	mono	N	O
-	:	-	-	-	N	O
infected	JJ	infected	infected	infect	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
18%	CD	18%	18%	18%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

3%	CD	3%	3%	3%	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
50	CD	50	50	50	N	O
-	:	-	-	-	N	O
mg	NN	mg	mg	mg	N	O
once	RB	once	once	onc	N	O
-	:	-	-	-	N	O
daily	JJ	daily	daily	daili	N	O
dose	NN	dose	dose	dose	N	O
and	CC	and	and	and	N	O
13%	CD	13%	13%	13%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

8%	CD	8%	8%	8%	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
50	CD	50	50	50	N	O
-	:	-	-	-	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
-	:	-	-	-	N	O
daily	JJ	daily	daily	daili	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

Liver	NNP	liver	liver	liver	N	B-AdverseReaction
chemistry	NN	chemistry	chemistry	chemistri	N	I-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
consistent	VBP	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
immune	JJ	immune	immune	immun	N	B-AdverseReaction
reconstitution	NN	reconstitution	reconstitution	reconstitut	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
C	NNP	c	c	c	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
start	NN	start	start	start	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
,	,	,	,	,	N	O
particularly	RB	particularly	particularly	particularli	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
setting	NN	setting	setting	set	N	O
where	WRB	where	where	where	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
therapy	NN	therapy	therapy	therapi	N	O
was	VBD	was	wa	wa	N	O
withdrawn	VBN	withdrawn	withdrawn	withdrawn	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
Serum	NNP	serum	serum	serum	N	O
Creatinine	NNP	creatinine	creatinine	creatinin	Y	O

Dolutegravir	NNP	dolutegravir	dolutegravir	dolutegravir	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
shown	VBN	shown	shown	shown	N	O
to	TO	to	to	to	N	O
increase	VB	increase	increase	increas	N	B-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
inhibition	NN	inhibition	inhibition	inhibit	N	O
of	IN	of	of	of	N	O
tubular	JJ	tubular	tubular	tubular	N	O
secretion	NN	secretion	secretion	secret	N	O
of	IN	of	of	of	N	O
creatinine	NN	creatinine	creatinine	creatinin	Y	O
without	IN	without	without	without	N	O
affecting	VBG	affecting	affecting	affect	N	O
renal	JJ	renal	renal	renal	N	O
glomerular	JJ	glomerular	glomerular	glomerular	N	O
function	NN	function	function	function	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.2	CD	12.2	12.2	12.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
4	CD	4	4	4	N	O
weeks	NNS	weeks	week	week	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
remained	VBD	remained	remained	remain	N	O
stable	JJ	stable	stable	stabl	N	O
through	IN	through	through	through	N	O
48	CD	48	48	48	N	O
to	TO	to	to	to	N	O
96	CD	96	96	96	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
naive	JJ	naive	naive	naiv	N	O
subjects	NNS	subjects	subject	subject	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
change	NN	change	change	chang	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
of	IN	of	of	of	N	O
0.15	CD	0.15	0.15	0.15	N	O
mg	NNS	mg	mg	mg	N	O
per	IN	per	per	per	N	O
dL	NN	dl	dl	dl	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
:	:	:	:	:	N	O
-	:	-	-	-	N	O
0.32	CD	0.32	0.32	0.32	N	O
mg	NN	mg	mg	mg	N	O
per	IN	per	per	per	N	O
dL	NN	dl	dl	dl	N	O
to	TO	to	to	to	N	O
0.65	CD	0.65	0.65	0.65	N	O
mg	NNS	mg	mg	mg	N	O
per	IN	per	per	per	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
after	IN	after	after	after	N	O
96	CD	96	96	96	N	O
weeks	NNS	weeks	week	week	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Creatinine	NN	creatinine	creatinine	creatinin	Y	B-AdverseReaction
increases	NNS	increases	increase	increas	N	I-AdverseReaction
were	VBD	were	were	were	N	O
comparable	JJ	comparable	comparable	compar	N	O
by	IN	by	by	by	N	O
background	NN	background	background	background	N	O
NRTIs	NNP	nrtis	nrti	nrti	N	O
and	CC	and	and	and	N	O
were	VBD	were	were	were	N	O
similar	JJ	similar	similar	similar	N	O
in	IN	in	in	in	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
experienced	JJ	experienced	experienced	experienc	N	O
subjects	NNS	subjects	subject	subject	N	O
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O
in	IN	in	in	in	N	O
Pediatric	NNP	pediatric	pediatric	pediatr	N	O
Subjects	NNS	subjects	subject	subject	N	O

IMPAACT	NNP	impaact	impaact	impaact	N	O
P1093	NNP	p1093	p1093	p1093	N	O
is	VBZ	is	is	is	N	O
an	DT	an	an	an	N	O
ongoing	JJ	ongoing	ongoing	ongo	N	O
multicenter	NN	multicenter	multicenter	multicent	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
,	,	,	,	,	N	O
non	SYM	non	non	non	N	O
-	:	-	-	-	N	O
comparative	JJ	comparative	comparative	compar	N	O
trial	NN	trial	trial	trial	N	O
of	IN	of	of	of	N	O
approximately	RB	approximately	approximately	approxim	N	O
160	CD	160	160	160	N	O
HIV	NNP	hiv	hiv	hiv	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
infected	VBN	infected	infected	infect	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
subjects	NNS	subjects	subject	subject	N	O
aged	VBD	aged	aged	age	N	O
6	CD	6	6	6	N	O
weeks	NNS	weeks	week	week	N	O
to	TO	to	to	to	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
18	CD	18	18	18	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
which	WDT	which	which	which	N	O
23	CD	23	23	23	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
experienced	VBN	experienced	experienced	experienc	N	O
,	,	,	,	,	N	O
INSTI	NNP	insti	insti	insti	N	O
-	:	-	-	-	N	O
naive	JJ	naive	naive	naiv	N	O
subjects	NNS	subjects	subject	subject	N	O
aged	VBD	aged	aged	age	N	O
12	CD	12	12	12	N	O
to	TO	to	to	to	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
18	CD	18	18	18	N	O
years	NNS	years	year	year	N	O
were	VBD	were	were	were	N	O
enrolled	VBN	enrolled	enrolled	enrol	N	O
[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.4	CD	8.4	8.4	8.4	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.2	CD	14.2	14.2	14.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
profile	NN	profile	profile	profil	N	O
was	VBD	was	wa	wa	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
that	DT	that	that	that	N	O
for	IN	for	for	for	N	O
adults	NNS	adults	adult	adult	N	O
.	.	.	.	.	N	O

Grade	$	grade	grade	grade	N	B-Severity
2	CD	2	2	2	N	I-Severity
ADRs	NNP	adrs	adrs	adr	N	O
reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
subject	JJ	subject	subject	subject	N	O
were	VBD	were	were	were	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
ADRs	NNS	adrs	adrs	adr	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
were	VBD	were	were	were	N	O
elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
total	JJ	total	total	total	N	I-AdverseReaction
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
and	CC	and	and	and	N	O
lipase	NN	lipase	lipase	lipas	Y	I-AdverseReaction
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
1	CD	1	1	1	N	O
subject	JJ	subject	subject	subject	N	O
each	DT	each	each	each	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
changes	NNS	changes	change	chang	N	O
in	IN	in	in	in	N	O
mean	JJ	mean	mean	mean	N	O
serum	NN	serum	serum	serum	N	O
creatinine	NN	creatinine	creatinine	creatinin	Y	O
were	VBD	were	were	were	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
those	DT	those	those	those	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
adults	NNS	adults	adult	adult	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
characterized	VBN	characterized	characterized	character	N	O
by	IN	by	by	by	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
constitutional	JJ	constitutional	constitutional	constitut	N	O
findings	NNS	findings	finding	find	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
organ	JJ	organ	organ	organ	N	B-AdverseReaction
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
liver	JJ	liver	liver	liver	N	B-AdverseReaction
injury	NN	injury	injury	injuri	Y	I-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
suspect	JJ	suspect	suspect	suspect	N	O
agents	NNS	agents	agent	agent	N	O
immediately	RB	immediately	immediately	immedi	N	O
if	IN	if	if	if	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
develop	VBP	develop	develop	develop	N	O
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
delay	NN	delay	delay	delay	N	O
in	IN	in	in	in	N	O
stopping	VBG	stopping	stopping	stop	N	O
treatment	NN	treatment	treatment	treatment	N	O
may	MD	may	may	may	N	O
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
life	NN	life	life	life	N	O
-	:	-	-	-	N	O
threatening	JJ	threatening	threatening	threaten	N	O
reaction	NN	reaction	reaction	reaction	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
underlying	JJ	underlying	underlying	underli	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
or	CC	or	or	or	N	O
C	NNP	c	c	c	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
worsening	VBG	worsening	worsening	worsen	N	O
or	CC	or	or	or	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
transaminase	NN	transaminase	transaminase	transaminas	N	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
with	IN	with	with	with	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
.	.	.	.	.	N	O

Appropriate	NNP	appropriate	appropriate	appropri	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
testing	VBG	testing	testing	test	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
for	IN	for	for	for	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
underlying	JJ	underlying	underlying	underli	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
disease	NN	disease	disease	diseas	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
or	CC	or	or	or	N	O
C.	NNP	c.	c.	c.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Redistribution	NNP	redistribution	redistribution	redistribut	N	B-AdverseReaction
accumulation	NN	accumulation	accumulation	accumul	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
body	NN	body	body	bodi	N	I-AdverseReaction
fat	JJ	fat	fat	fat	N	I-AdverseReaction
and	CC	and	and	and	N	O
immune	JJ	immune	immune	immun	N	B-AdverseReaction
reconstitution	NN	reconstitution	reconstitution	reconstitut	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
combination	NN	combination	combination	combin	N	B-DrugClass
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	I-DrugClass
therapy	NN	therapy	therapy	therapi	N	I-DrugClass
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
,	,	,	,	,	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O

Reactions	NNS	reactions	reaction	reaction	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
and	CC	and	and	and	N	O
were	VBD	were	were	were	N	O
characterized	VBN	characterized	characterized	character	N	O
by	IN	by	by	by	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
constitutional	JJ	constitutional	constitutional	constitut	N	O
findings	NNS	findings	finding	find	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
sometimes	RB	sometimes	sometimes	sometim	N	O
organ	JJ	organ	organ	organ	N	B-AdverseReaction
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
liver	JJ	liver	liver	liver	N	B-AdverseReaction
injury	NN	injury	injury	injuri	Y	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
in	IN	in	in	in	N	O
Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
suspect	JJ	suspect	suspect	suspect	N	O
agents	NNS	agents	agent	agent	N	O
immediately	RB	immediately	immediately	immedi	N	O
if	IN	if	if	if	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
develop	VBP	develop	develop	develop	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
not	RB	not	not	not	N	O
limited	JJ	limited	limited	limit	N	O
to	TO	to	to	to	N	O
,	,	,	,	,	N	O
severe	JJ	severe	severe	sever	N	O
rash	NN	rash	rash	rash	Y	O
or	CC	or	or	or	N	O
rash	NN	rash	rash	rash	Y	O
accompanied	VBN	accompanied	accompanied	accompani	N	O
by	IN	by	by	by	N	O
fever	NN	fever	fever	fever	Y	O
,	,	,	,	,	N	O
general	JJ	general	general	gener	N	O
malaise	NN	malaise	malaise	malais	Y	O
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	O
,	,	,	,	,	N	O
muscle	NN	muscle	muscle	muscl	N	O
or	CC	or	or	or	N	O
joint	JJ	joint	joint	joint	N	O
aches	NNS	aches	ache	ach	N	O
,	,	,	,	,	N	O
blisters	NNS	blisters	blister	blister	Y	O
or	CC	or	or	or	N	O
peeling	NN	peeling	peeling	peel	Y	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
skin	NN	skin	skin	skin	N	O
,	,	,	,	,	N	O
oral	JJ	oral	oral	oral	N	O
blisters	NNS	blisters	blister	blister	Y	O
or	CC	or	or	or	N	O
lesions	NNS	lesions	lesion	lesion	N	O
,	,	,	,	,	N	O
conjunctivitis	NN	conjunctivitis	conjunctivitis	conjunct	Y	O
,	,	,	,	,	N	O
facial	JJ	facial	facial	facial	N	O
edema	NN	edema	edema	edema	Y	O
,	,	,	,	,	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
,	,	,	,	,	N	O
eosinophilia	NN	eosinophilia	eosinophilia	eosinophilia	Y	O
,	,	,	,	,	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	O
,	,	,	,	,	N	O
difficulty	NN	difficulty	difficulty	difficulti	N	O
breathing	NN	breathing	breathing	breath	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
status	NN	status	status	statu	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
liver	NN	liver	liver	liver	N	O
aminotransferases	NNS	aminotransferases	aminotransferase	aminotransferas	N	O
,	,	,	,	,	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
and	CC	and	and	and	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
therapy	NN	therapy	therapy	therapi	N	O
initiated	VBN	initiated	initiated	initi	N	O
.	.	.	.	.	N	O

Delay	NN	delay	delay	delay	N	O
in	IN	in	in	in	N	O
stopping	VBG	stopping	stopping	stop	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
suspect	JJ	suspect	suspect	suspect	N	O
agents	NNS	agents	agent	agent	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
onset	NN	onset	onset	onset	N	O
of	IN	of	of	of	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
may	MD	may	may	may	N	O
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
life	NN	life	life	life	N	O
-	:	-	-	-	N	O
threatening	JJ	threatening	threatening	threaten	N	O
reaction	NN	reaction	reaction	reaction	N	O
.	.	.	.	.	N	O

TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
is	VBZ	is	is	is	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
experienced	VBN	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
previous	JJ	previous	previous	previou	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reaction	NN	reaction	reaction	reaction	N	O
to	TO	to	to	to	N	O
dolutegravir	VB	dolutegravir	dolutegravir	dolutegravir	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Effects	NNS	effects	effect	effect	N	O
on	IN	on	on	on	N	O
Serum	NNP	serum	serum	serum	N	O
Liver	NNP	liver	liver	liver	N	O
Biochemistries	NNP	biochemistries	biochemistry	biochemistri	N	O
in	IN	in	in	in	N	O
Patients	NNP	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Hepatitis	NNP	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
or	CC	or	or	or	N	O
C	NNP	c	c	c	N	O
Co	NNP	co	co	co	N	O
-	:	-	-	-	N	O
infection	NN	infection	infection	infect	Y	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
underlying	JJ	underlying	underlying	underli	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
or	CC	or	or	or	N	O
C	NNP	c	c	c	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
worsening	VBG	worsening	worsening	worsen	N	O
or	CC	or	or	or	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
transaminase	NN	transaminase	transaminase	transaminas	N	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
with	IN	with	with	with	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
some	DT	some	some	some	N	O
cases	NNS	cases	case	case	N	O
the	DT	the	the	the	N	O
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
immune	JJ	immune	immune	immun	N	B-AdverseReaction
reconstitution	NN	reconstitution	reconstitution	reconstitut	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
or	CC	or	or	or	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	B-AdverseReaction
B	NNP	b	b	b	N	I-AdverseReaction
reactivation	NN	reactivation	reactivation	reactiv	N	I-AdverseReaction
particularly	RB	particularly	particularly	particularli	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
setting	NN	setting	setting	set	N	O
where	WRB	where	where	where	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
therapy	NN	therapy	therapy	therapi	N	O
was	VBD	was	wa	wa	N	O
withdrawn	VBN	withdrawn	withdrawn	withdrawn	Y	O
.	.	.	.	.	N	O

Appropriate	NNP	appropriate	appropriate	appropri	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
testing	VBG	testing	testing	test	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
for	IN	for	for	for	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
are	VBP	are	are	are	N	O
recommended	VBN	recommended	recommended	recommend	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
underlying	JJ	underlying	underlying	underli	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
disease	NN	disease	disease	diseas	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
B	NNP	b	b	b	N	O
or	CC	or	or	or	N	O
C.	NNP	c.	c.	c.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Fat	NNP	fat	fat	fat	N	O
Redistribution	NNP	redistribution	redistribution	redistribut	N	O

Redistribution	NNP	redistribution	redistribution	redistribut	N	B-AdverseReaction
accumulation	NN	accumulation	accumulation	accumul	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
body	NN	body	body	bodi	N	I-AdverseReaction
fat	JJ	fat	fat	fat	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
central	JJ	central	central	central	N	B-AdverseReaction
obesity	NN	obesity	obesity	obes	Y	I-AdverseReaction
,	,	,	,	,	N	O
dorsocervical	JJ	dorsocervical	dorsocervical	dorsocerv	N	B-AdverseReaction
fat	NN	fat	fat	fat	N	I-AdverseReaction
enlargement	NN	enlargement	enlargement	enlarg	N	I-AdverseReaction
(	(	(	(	(	N	O
buffalo	JJ	buffalo	buffalo	buffalo	N	B-AdverseReaction
hump	NN	hump	hump	hump	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	I-AdverseReaction
wasting	NN	wasting	wasting	wast	Y	I-AdverseReaction
,	,	,	,	,	N	O
facial	JJ	facial	facial	facial	N	B-AdverseReaction
wasting	NN	wasting	wasting	wast	Y	I-AdverseReaction
,	,	,	,	,	N	O
breast	NN	breast	breast	breast	N	B-AdverseReaction
enlargement	NN	enlargement	enlargement	enlarg	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
"	NNP	"	"	"	N	O
cushingoid	VBP	cushingoid	cushingoid	cushingoid	Y	B-AdverseReaction
appearance	NN	appearance	appearance	appear	N	I-AdverseReaction
"	NNS	"	"	"	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	B-DrugClass
therapy	NN	therapy	therapy	therapi	N	I-DrugClass
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mechanism	NN	mechanism	mechanism	mechan	N	O
and	CC	and	and	and	N	O
long	JJ	long	long	long	N	O
-	:	-	-	-	N	O
term	NN	term	term	term	N	O
consequences	NNS	consequences	consequence	consequ	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
are	VBP	are	are	are	N	O
currently	RB	currently	currently	current	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
established	VBN	established	established	establish	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Immune	NNP	immune	immune	immun	N	O
Reconstitution	NNP	reconstitution	reconstitution	reconstitut	N	O
Syndrome	NNP	syndrome	syndrome	syndrom	N	O

Immune	NNP	immune	immune	immun	N	B-AdverseReaction
reconstitution	NN	reconstitution	reconstitution	reconstitut	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
combination	NN	combination	combination	combin	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
TIVICAY	NNP	tivicay	tivicay	tivicay	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
initial	JJ	initial	initial	initi	N	O
phase	NN	phase	phase	phase	N	O
of	IN	of	of	of	N	O
combination	NN	combination	combination	combin	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
whose	WP$	whose	whose	whose	N	O
immune	JJ	immune	immune	immun	N	O
systems	NNS	systems	system	system	N	O
respond	NN	respond	respond	respond	N	O
may	MD	may	may	may	N	B-Factor
develop	VB	develop	develop	develop	N	O
an	DT	an	an	an	N	O
inflammatory	JJ	inflammatory	inflammatory	inflammatori	N	B-AdverseReaction
response	NN	response	response	respons	N	I-AdverseReaction
to	TO	to	to	to	N	O
indolent	NN	indolent	indolent	indol	N	O
or	CC	or	or	or	N	O
residual	JJ	residual	residual	residu	N	B-AdverseReaction
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
(	(	(	(	(	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
Mycobacterium	NNP	mycobacterium	mycobacterium	mycobacterium	N	B-AdverseReaction
avium	NN	avium	avium	avium	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
cytomegalovirus	NN	cytomegalovirus	cytomegalovirus	cytomegaloviru	N	B-AdverseReaction
,	,	,	,	,	N	O
Pneumocystis	NNP	pneumocystis	pneumocystis	pneumocysti	N	B-AdverseReaction
jirovecii	NN	jirovecii	jirovecii	jirovecii	N	I-AdverseReaction
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
PCP	NNP	pcp	pcp	pcp	N	B-AdverseReaction
]	NNP	]	]	]	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	B-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
necessitate	VB	necessitate	necessitate	necessit	N	O
further	JJ	further	further	further	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
and	CC	and	and	and	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Autoimmune	NNP	autoimmune	autoimmune	autoimmun	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
(	(	(	(	(	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
Graves	NNS	graves	graf	grave	N	B-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
,	,	,	,	,	N	O
polymyositis	NN	polymyositis	polymyositis	polymyos	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Guillain	NNP	guillain	guillain	guillain	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Barre	NNP	barre	barre	barr	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
to	TO	to	to	to	N	O
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
setting	NN	setting	setting	set	N	O
of	IN	of	of	of	N	O
immune	JJ	immune	immune	immun	N	O
reconstitution	NN	reconstitution	reconstitution	reconstitut	N	O
;	:	;	;	;	N	O
however	RB	however	however	howev	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
onset	VB	onset	onset	onset	N	O
is	VBZ	is	is	is	N	O
more	RBR	more	more	more	N	O
variable	JJ	variable	variable	variabl	N	O
and	CC	and	and	and	N	O
can	MD	can	can	can	N	O
occur	VB	occur	occur	occur	N	O
many	JJ	many	many	mani	N	O
months	NNS	months	month	month	N	O
after	IN	after	after	after	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

